The FDA Center for Veterinary Medicine has granted Bayer Animal Health a conditional approval for Baytril 100-CA1 (enrofloxacin) Injectable Solution for the treatment of clinical anaplasmosis in cattle. The product will be available to veterinarians and cattle producers in May 2020. “This conditional approval allows us to offer the proven efficacy of enrofloxacin as a new treatment for this potentially deadly disease,” said Sebastian Kuszmierczyk, head of farm animal products in the US for Bayer Animal Health. Until now, tetracycline antimicrobials, oxytetracycline injectables or chlortetracycline medicated feed were the only drugs used in the US for treatment of acute anaplasmosis.
Baytril 100-CA1 contains the proven molecule enrofloxacin, and is indicated for the treatment of clinical anaplasmosis associated with Anaplasma marginalein all classes of beef cattle except beef calves less than 2 months of age and beef bulls intended for breeding of any age. Baytril 100-CA1 is conditionally approved pending a full demonstration of effectiveness. Baytril 100-CA1 has a reasonable expectation of effectiveness for treatment of clinical anaplasmosis in the conditionally approved classes of cattle, when it is administered for the conditionally approved dosage regimen based on published scientific literature and reports from studies conducted by the sponsor. Enrofloxacin treatment in cattle infected with A. marginale resulted in a decrease in parasitemia and, when evaluated, improvement in clinical variables (hematocrit and rectal temperatures),
Description
Baytril® 100-CA1 contains the proven molecule, enrofloxacin, and is indicated for the treatment of clinical anaplasmosis associated with Anaplasma marginale in replacement dairy heifers under 20 months of age, all classes of beef cattle except beef calves less than 2 months of age and beef bulls intended for breeding of any age. Not for use in any other class of dairy cattle or in veal calves.
Baytril® 100-CA1 is conditionally approved pending a full demonstration of effectiveness. Baytril® 100-CA1 has a reasonable expectation of effectiveness for treatment of clinical anaplasmosis in the conditionally approved classes of cattle when administered for the conditionally approved dosage regimen based on published scientific literature and reports from studies conducted by the sponsor. Enrofloxacin treatment in A. marginale-infected cattle resulted in a decrease in parasitemia and, when evaluated, improvement in clinical variables (hematocrit and rectal temperatures).
Indication:
Baytril® 100-CA1 is indicated for the treatment of clinical anaplasmosis associated with Anaplasma marginale in replacement dairy heifers under 20 months of age and all classes of beef cattle except beef calves less than 2 months of age and beef bulls intended for breeding (any age). Not for use in any other class of dairy cattle or in veal calves.
Dosage/administration:
Baytril® 100-CA1 should be administered as a single dose for treatment of clinical anaplasmosis. Administer, by subcutaneous injection, a single dose of 12.5 mg/kg of body weight (5.7 mL/100 lb). Administered dose volume should not exceed 20 mL per injection site.
| Weight (lb) | Single-Dose Therapy 12.5 mg/kg Dose Volume (mL) |
| 500 | 28.5 |
| 600 | 34.0 |
| 700 | 40.0 |
| 800 | 45.5 |
| 900 | 51.5 |
| 1000 | 57.0 |
| 1100 | 62.5 |
| 1200 | 68.5 |
| 1300 | 74.0 |
| 1400 | 80.0 |
| 1500 | 85.5 |
| 1600 | 91.0 |
| 1700 | 97.0 |
| 1800 | 102.5 |
| 1900 | 108.5 |
| 2000 | 114.0 |
| *Dose volumes have been rounded to the nearest 0.5 mL. |
Prices of Baytril 100 Ca1
$30.99 – $158.29